We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Totally Resistant Tuberculosis Appears in India

By HospiMedica International staff writers
Posted on 30 Jan 2012
Four patients with tuberculosis (TB) resistant to five front-line drugs and seven second-line medications have been identified in India, making them virtually untreatable with available medications.

Researchers at PD Hinduja National Hospital and Medical Research Center (Mumbai, India) reported on the four patients, who were resistant to isoniazid, rifampicin, ethambutol, pyrazinamide, and streptomycin--the standard first-line drugs--as well as ofloxacin moxifloxacin, kanamycin, amikacin, capreomycin, para-aminosalicylic acid, and ethionamide. More...
In three of the cases, the researchers conducted a careful analysis of their prescriptions and found that in an effort to cure their multidrug-resistant TB (MDR-TB), each had been given erratic, unsupervised second-line drugs, added individually and often in incorrect doses, from multiple private practitioners over an 18-month period.

As a result, the patients are now classified as more than extensively drug-resistant TB (XDR-TB), and have become totally drug-resistant TB (TDR-TB). These patients are the first in a series of 12 cases that have emerged since doctors at the institution began grappling with increasingly resistant strains of TB. The researchers blamed the rise of such resistance on India's healthcare system, which has had some success against normal TB, but which they said does not pay enough attention to resistant strains. As a result, many patients with resistant TB go to unqualified private physicians, resulting in inadequate care that leads to increasing resistance, rather than cure. The cases were reported in a letter published online on December 21, 2011, in Clinical Infectious Diseases.

“We must ensure treatment adherence to minimize interruption. We must also ensure the selection and use of appropriate drug regimens and rapid diagnostics so that people with drug resistant TB are started on the correct regimens at the right time,” said lead author Zarir Udwadia, MD.

The TB bacterium in most cases succumbs to a regimen consisting of isoniazid, rifampin, ethambutol, and pyrazinamide for eight weeks, followed by isoniazid and rifampin for another 18 weeks. But inadequate or interrupted treatment can lead to resistance; MDR-TB is resistant to isoniazid and rifampin, although other first-line drugs and several second-line drugs remain available. XDR-TB is resistant to isoniazid and rifampin, as well as any fluoroquinolone and at least one of three injectable second-line drugs, such as amikacin, kanamycin, or capreomycin.

Related Links:

PD Hinduja National Hospital and Medical Research Center


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Medical-Grade Display
HL2316SHTB
New
Pediatric Mask
Respire SOFT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Six-month FlexPulse IDE data show positive outcomes with Abbott’s TactiFlex Duo catheter, confirming safety and efficacy seen in the CE Mark study for complex AFib (photo courtesy of Abbott)

Dual-Energy Ablation and Conduction System Pacing Show Positive Early Outcomes

Atrial fibrillation and other arrhythmias are common in both hospitalized and ambulatory patients, often complicating hemodynamic stability, stroke prevention, and perioperative care. Within this context,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.